Pharma Stability: Insights, Guidelines, and Expertise
The stability of biologics is governed by a delicate balance of electrostatic and hydrophobic interactions. Altering the pH or ionic strength can shift this balance, potentially leading to:
Click to read the full article.
Intermediate stability studies are not just fallback tests—they provide essential insight into how products behave under modest stress. These studies serve to:
Click to read the full article.
Available from Pharma SOP:
Click to read the full article.
Available from Pharma SOP:
Click to read the full article.
Available from Pharma SOP:
Click to read the full article.
Biologic drugs are particularly sensitive to process changes. As production moves from laboratory or pilot scale to full-scale manufacturing, changes in:
Click to read the full article.
Combination products are regulated entities that consist of two or more components combined to achieve therapeutic or diagnostic functionality. These include:
Click to read the full article.
Packaging material is in constant contact with the pharmaceutical product, especially for oral liquids, injectables, and inhalers. Over time, this can lead to:
Click to read the full article.
Available from Pharma SOP:
Click to read the full article.
Biologic drugs, especially injectables and parenterals, are highly susceptible to microbial intrusion due to their aqueous formulations, complex storage requirements, and sensitive molecular structures. Contamination during stability testing can lead to:
Click to read the full article.